Background

On the 17th January 2020 in response to the emergence of SARS-CoV-2 the UK triggered a national characterisation protocol, Clinical Characterisation Protocol-UK (CCP-UK). Information on co-morbidities including malignant neoplasm is recorded and following an amendment in April 2020 a history of active cancer treatment. A lack of large scale prospective data regarding cancer patients with COVID-19 hampers the development of an evidence based approach in this population. While the lack of comparative data between a contemporaneous cancer and non-cancer population hospitalised with COVID-19 prevents a true understanding of the impact of cancer and its treatments on the presentation, clinical course and outcomes of cancer patients with COVID-19.

Method

Patients admitted with proven SARS-CoV-2 infection and registered on CCP-UK from 17th January onwards in 258 healthcare facilities in the UK. Case report forms were used to identify patients with a history of malignant neoplasm or on active treatment for cancer. Analysis is restricted to outcome of patients who were admitted >14 days before data extraction. Patients with a history of cancer and on active treatments were compared to those patients with no history of cancer.

Clinical trial identification ISRCTN66726260

Results

As of the 17th August 2020 78,603 patients were registered on CCP-UK. With 66,594 having complete outcomes of these 59,568 (89.5%) had no history of cancer and 7,026 (10.5%) having cancer:5,346 (8.0%) had a history of cancer and 1,680 (2.5%) were on active treatment.  Registration of cases on CCP-UK continues.

An up to date analysis will be undertaken prior to the meeting and the following data presented:

• Demographics, co-morbidities, symptoms at presentation, escalation of care to critical care facilities, the use of invasive mechanical ventilation and outcomes. 
• Comparison will be made between the non-cancer patients, patients with a history of cancer and patients on active treatment.

Conclusion

Impact statement